Use

This next-generation sequencing panel of 523 genes provides personalized genomic analysis of a patient’s tumor to support precision oncology, including detection of single nucleotide variants, small insertions/deletions, copy‑number alterations, and translocations. It additionally assesses microsatellite instability (MSI) and tumor mutation burden (TMB), facilitating evaluation of eligibility for immune checkpoint inhibitors and aiding treatment selection, prognosis, and clinical trial planning. Any significant findings are annotated per AMP guidelines and reviewed by a Quest pathologist for physician reporting.